Invention Grant
- Patent Title: Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them
-
Application No.: US16498207Application Date: 2018-03-28
-
Publication No.: US11603367B2Publication Date: 2023-03-14
- Inventor: Steven Howard , Jeffrey David St. Denis , Charlotte Mary Griffiths-Jones , Steven Douglas Hiscock , Alan Richard Burns , David Cousin , Kim Louise Hirst , James Daniel Osborne , Jonas Calleja Priede , Aaron Michael Dumas , Brian Christopher Bishop , David Parry-Jones , Jeremy Peter Scott , Meenakshi Sundaram Shanmugham , Peter Richard Mullens , Darren James Dixon , Matthew James Gaunt
- Applicant: ASTEX THERAPEUTICS LIMITED , CANCER RESEARCH TECHNOLOGY LIMITED
- Applicant Address: GB Cambridge; GB London
- Assignee: ASTEX THERAPEUTICS LIMITED,CANCER RESEARCH TECHNOLOGY LIMITED
- Current Assignee: ASTEX THERAPEUTICS LIMITED,CANCER RESEARCH TECHNOLOGY LIMITED
- Current Assignee Address: GB Cambridge; GB London
- Agency: Heslin Rothenberg Farley & Mesiti P.C.
- Priority: GB1704965 20170328
- International Application: PCT/GB2018/050845 WO 20180328
- International Announcement: WO2018/178691 WO 20181004
- Main IPC: C07D405/06
- IPC: C07D405/06
Abstract:
The invention relates to processes for preparing isoindolin-1-one derivatives, and in particular processes for preparing (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid. The invention also relates to crystalline forms of the compound (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid and its salts.
Public/Granted literature
- US20210101887A1 ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM Public/Granted day:2021-04-08
Information query
